Immunovant, Inc. (BOATS:IMVT) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: about US$550M · US$21 a share · Leerink Partners Dealers: Leerink Partners (lead) Buyers: Roivant Sciences Ltd. Insiders: Roivant Sciences Ltd., the controlling stockholder, has agreed to purchase shares in the offering Use of proceeds: Fund operating expenses and capital expenditures through the potential commercial launch of IMVT-1402 in Graves’ Disease | Dec 11, 2025 |
| Private placement of shares of common stock Announced: about US$450M · US$20 a share Buyers: Roivant Use of proceeds: Advancement of its development pipeline, working capital and other general corporate purposes | Jan 13, 2025 |